#JPM20: Five years af­ter first PC­SK9, No­var­tis goes for win as Sanofi moves on, Am­gen sal­vages what's left

Paul Hud­son

SAN FRAN­CIS­CO — Sanofi CEO Paul Hud­son spent ze­ro sec­onds of his pre­sen­ta­tion talk­ing about a car­dio­vas­cu­lar drug his com­pa­ny spent years de­vel­op­ing.

Robert Brad­way of Am­gen, the com­pa­ny whose ri­val prod­uct was so for­mi­da­ble Sanofi and their part­ner Re­gen­eron spent $67.5 mil­lion on a pri­or­i­ty re­view vouch­er to get theirs ap­proved faster, bare­ly touched on the drug. “We’ve made con­sid­er­able progress dur­ing the course of the year on im­prov­ing ac­cess to Repatha,” Brad­way said at his pre­sen­ta­tion, gloss­ing on the com­pa­ny’s deep strug­gles to sell a drug once billed as a po­ten­tial megablock­buster.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER